Back to top

Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $553 from $542 and keeps a Neutral rating on the shares. The firm updated...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Madrigal Pharmaceuticals, Inc. (MDGL)